|
|
|
|
||
Re: Stanford team reports live imaging of CAR T cells in collaboration with researchers from Sangamo BioSciences Inc. (NASDAQ:SGMO)bogous i dont know no license tocellcyrte what i know on cellcyte: CellCyte Genetics The SEC (www.sec.gov) filed suit against former Chief Executive Officer Gary Reys and former Chief Scientific Officer Ronald Berninger of CellCyte Genetics, WA, USA (www.cellcyte.com), for falsely telling investors that the company’s cutting- edge stem cell technology had been proven successful and was headed for human trials. CellCyte falsely claimed that it had received FDA approval to begin human clinical trials with a special stem cell compound to repair the heart. The SEC alleges that CellCyte did not know how to properly formulate the stem cell compound, had never attempted experiments with the compound to repair organs and had not satisfied any of the FDA requirements to begin human clinical trials. Furthermore, CellCyte engaged in an illegal stock distribution by partnering with a Canadian stock promoter, who sent millions of spam emails, faxes and newsletters containing false information about CellCyte. During the promotional campaign from August to December 2007, CellCyte’s stock price rose from $4.00 to $7.50, briefly giving the fledgling company a market capitalization of nearly $450 million. The stock now trades at less than $0.08 per share, leaving investors who were deceived by the fraudulent materials with massive losses. someone ask biocentury for clarification http://www.biocentury.com/ContactUS/LocationsAndDepartments |
return to message board, top of board |